A randomized trial comparing 4.8 vs. 2.4g/day of oral mesalazine for maintenance of remission in ulcerative colitis

Variation Between Observers in Describing Mucosal Appearances in Proctocolitis

J H Baron, Alastair M. Connell, J E Lennard-Jones · BMJ · 1964 · 618 citations · Full text

Medicine, Neurology, Neuroscience +17

Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis

Alain Bitton, Mark A. Peppercorn, Donald A. Antonioli et al. · Gastroenterology · 2001 · 487 citations · Full text

Medicine, Immunology, Pathology +14

Biopsy Studies in Ulcerative Colitis

S. C. Truelove, Warren Richards · BMJ · 1956 · 393 citations · Full text

Medicine, Clinical Sciences, Pathology +14

Delayed-Release Oral Mesalamine at 4.8 g/day (800 mg tablet) for the Treatment of Moderately Active Ulcerative Colitis: The ASCEND II Trial

Stephen B. Hanauer, William J. Sandborn, Asher Kornbluth et al. · The American Journal of Gastroenterology · 2005 · 323 citations

Medicine, Pharmacology, Pharmacotherapy +9

Rectal biopsy helps to distinguish acute self-limited colitis from idiopathic inflammatory bowel disease

Christina M. Surawicz, Lanie Belic · Gastroenterology · 1984 · 312 citations

Medicine, Internal Medicine, Pathology +9